RECURSION PHARMACEUTICALS, INC. Restructuring Charges
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Restructuring Charges of $9.84 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-02-25
- RECURSION PHARMACEUTICALS, INC. restructuring charges for the quarter ending 2025-12-31 was $1.32M.
- RECURSION PHARMACEUTICALS, INC. restructuring charges for the quarter ending 2025-09-30 was $73.00K.
- RECURSION PHARMACEUTICALS, INC. restructuring charges for fiscal 2025 was $9.84M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.39M derived: sum of 2 quarters · filed 2026-02-25 | $9.84M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $73.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $8.52M 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | $8.44M 10-Q · filed 2025-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |